AR113430A1 - Proteína de fusión enzimática terapéutica que tiene una nueva estructura y su uso - Google Patents

Proteína de fusión enzimática terapéutica que tiene una nueva estructura y su uso

Info

Publication number
AR113430A1
AR113430A1 ARP180103796A ARP180103796A AR113430A1 AR 113430 A1 AR113430 A1 AR 113430A1 AR P180103796 A ARP180103796 A AR P180103796A AR P180103796 A ARP180103796 A AR P180103796A AR 113430 A1 AR113430 A1 AR 113430A1
Authority
AR
Argentina
Prior art keywords
fusion protein
enzyme
new structure
therapeutic
enzymatic fusion
Prior art date
Application number
ARP180103796A
Other languages
English (en)
Inventor
Sung Youb Jung
In Young Choi
Jin Young Kim
Eui Joon Jeong
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR113430A1 publication Critical patent/AR113430A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase

Abstract

La presente se refiere a una proteína de fusión entre una enzima terapéutica dimérica y una región Fc de inmunoglobulina, un método de preparación del mismo y una composición que comprende la proteína de fusión. Reivindicación 1: Una proteína de fusión enzimática de la fórmula (1); donde X y X’ son cada uno de modo independiente el mismo tipo o diferente de enzima terapéutica; L y L’ son ligadores, cada uno de modo independiente el mismo tipo o diferente de ligador; F es una región Fc de inmunoglobulina; | es un enlace covalente; y : es un enlace covalente o no covalente. Reivindicación 6: La proteína de fusión enzimática de la reivindicación 5, donde la enzima es a-galactosidasa A o b-galactosidasa.
ARP180103796A 2017-12-22 2018-12-21 Proteína de fusión enzimática terapéutica que tiene una nueva estructura y su uso AR113430A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20170178378 2017-12-22

Publications (1)

Publication Number Publication Date
AR113430A1 true AR113430A1 (es) 2020-04-29

Family

ID=66993643

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103796A AR113430A1 (es) 2017-12-22 2018-12-21 Proteína de fusión enzimática terapéutica que tiene una nueva estructura y su uso

Country Status (17)

Country Link
US (1) US20210009984A1 (es)
EP (1) EP3708661A4 (es)
JP (1) JP7403455B2 (es)
KR (2) KR102588611B1 (es)
CN (1) CN111511910A (es)
AR (1) AR113430A1 (es)
AU (1) AU2018388331A1 (es)
BR (1) BR112020012346A2 (es)
CA (1) CA3086474A1 (es)
EA (1) EA202091239A1 (es)
IL (1) IL275248A (es)
MX (1) MX2020006635A (es)
NZ (1) NZ765453A (es)
PH (1) PH12020550927A1 (es)
SG (1) SG11202005510SA (es)
TW (1) TW201934753A (es)
WO (1) WO2019125059A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021024864A (ja) * 2019-08-07 2021-02-22 アミカス セラピューティックス インコーポレイテッド Ｇｌａ遺伝子に突然変異を有する患者のファブリー病を治療する方法
KR20230086703A (ko) 2020-10-14 2023-06-15 데날리 테라퓨틱스 인크. 설포글루코사민 설포하이드롤라제 효소를 포함하는 융합 단백질 및 이의 방법
AU2021377712A1 (en) * 2020-11-13 2023-06-01 Hanmi Pharm. Co., Ltd. Use of therapeutic enzyme fusion protein in prevention and treatment of neuropathy caused by or accompanied by Fabry disease
CN116419760A (zh) * 2020-11-13 2023-07-11 韩美药品株式会社 治疗酶融合蛋白在预防和治疗由法布里病引起或伴有法布里病的肾病中的用途
KR20230134822A (ko) * 2022-03-15 2023-09-22 주식회사 녹십자 α-갈락토시다제 A의 융합단백질을 포함하는 액상 제제
KR20230134823A (ko) * 2022-03-15 2023-09-22 주식회사 녹십자 α-갈락토시다제 A의 융합단백질을 포함하는 동결 건조 제제

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU215180B (hu) * 1992-01-23 1998-10-28 Merck Patent Gmbh. Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
RU2002110121A (ru) * 1999-09-17 2004-03-10 Джитиси Байотерапьютикс, Инк. (Us) Слитые белки, полученные трансгенным способом
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
NZ561374A (en) * 2005-04-11 2009-02-28 Sanofi Pasteur Polymyxin B analogs for LPS detoxification
CA2635623C (en) * 2005-12-30 2015-02-17 Michael Super Anti-cd19 antibodies with reduced immunogenicity
EP2162472B1 (en) * 2007-05-30 2013-02-27 Postech Academy-Industry- Foundation Immunoglobulin fusion proteins
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
MX2016001165A (es) * 2013-07-31 2016-06-29 Amgen Inc Estabilizacion de polipeptidos que contienen fragmentos cristalizables.
TN2017000271A1 (en) * 2014-12-30 2018-10-19 Hanmi Pharm Ind Co Ltd Glucagon derivative having improved stability
EP3359192A4 (en) * 2015-10-08 2019-05-01 MacroGenics, Inc. POLY THERAPY FOR THE TREATMENT OF CANCER
CA3006460A1 (en) * 2015-12-08 2017-06-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
WO2019009684A2 (ko) * 2017-07-07 2019-01-10 한미약품 주식회사 신규 치료학적 효소 융합단백질 및 이의 용도

Also Published As

Publication number Publication date
MX2020006635A (es) 2020-12-10
TW201934753A (zh) 2019-09-01
EA202091239A1 (ru) 2020-09-09
JP7403455B2 (ja) 2023-12-22
KR20230143985A (ko) 2023-10-13
KR102588611B1 (ko) 2023-10-16
CN111511910A (zh) 2020-08-07
NZ765453A (en) 2024-03-22
BR112020012346A2 (pt) 2020-11-24
WO2019125059A1 (ko) 2019-06-27
US20210009984A1 (en) 2021-01-14
KR20190076909A (ko) 2019-07-02
JP2021507705A (ja) 2021-02-25
PH12020550927A1 (en) 2021-05-10
CA3086474A1 (en) 2019-06-27
IL275248A (en) 2020-07-30
EP3708661A1 (en) 2020-09-16
EP3708661A4 (en) 2021-12-01
AU2018388331A1 (en) 2020-07-02
SG11202005510SA (en) 2020-07-29

Similar Documents

Publication Publication Date Title
AR113430A1 (es) Proteína de fusión enzimática terapéutica que tiene una nueva estructura y su uso
AU2022228122B2 (en) Interleukin-21 muteins and methods of treatment
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
PH12020550650A1 (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
CL2022000097A1 (es) Proteínas de fusión fc heterodiméricas il15/il15ralfa (divisional de la solicitud no. 201901000)
CL2022000036A1 (es) Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261)
CO2019014682A2 (es) Composiciones y métodos para enzimas de internalización
CO2017002166A2 (es) Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
CY1120485T1 (el) Μεθοδοι για τη συζευξη πεπτιδιων-στοχων με ανασυνδυασμενα λυσοσωμικα ενζυμα για βελτιωμενες θεραπευτικες αγωγες διαταραχων λυσοσωμικης αποθηκευσης
CY1117695T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα της ανθρωπινης αγγειοποιητινης-2
BR112019008854A2 (pt) ligantes contendo peptídeo para conjugados de anticorpo-fármaco
PE20181300A1 (es) Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer
PE20170908A1 (es) VARIANTES DE INTERFERON a2b
MX2018013784A (es) Proteinas de fusion gdf15 y usos de estas.
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
BR112021016435A2 (pt) Receptores de antígenos quiméricos responsivos à hipóxia
AR118193A1 (es) Derivados de heterociclos bicíclicos fusionados como pesticidas
CL2018000131A1 (es) Inmunoconjugados de il22
AU2018249796A1 (en) Antibody Fc variants for improving blood half-life
MX2017010359A (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
WO2017015634A3 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
EA201991702A1 (ru) Самосборные белковые наночастицы, инкапсулирующие иммуностимулирующие нуклеиновые кислоты
BR112021011595A2 (pt) Proteína biespecífica